Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06897202 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM

A Phase 2 study of Type 2 Diabetes Mellitus (T2DM) and Obesity in Diabetes, sponsored by Metsera, a wholly owned subsidiary of Pfizer.

Active
Registry status
Phase 2
Development phase
133
Enrollment target
20
Study locations

NCT06897202 is a Phase 2 study of Type 2 Diabetes Mellitus (T2DM) and Obesity in Diabetes that is active but no longer recruiting, run by Metsera, a wholly owned subsidiary of Pfizer. The registered enrollment target is 133 participants, below the 517-participant average among 24 other Type 2 Diabetes Mellitus (T2DM) trials with a reported enrollment target (74% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06897202, a Phase 2 study of Type 2 Diabetes Mellitus (T2DM) and Obesity in Diabetes, is active but no longer recruiting, sponsored by Metsera, a wholly owned subsidiary of Pfizer.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
133 participants
Enrollment target
20
Study locations

Study Summary

This study is designed to test how well once-weekly MET097 (an ultra-long-acting GLP-1 receptor agonist) works to treat adults with obesity or overweight and type 2 diabetes mellitus (T2DM) compared to placebo. MET097 or placebo will be administered to individuals via subcutaneous injection once weekly for 28 weeks. If an individual is randomly assigned to MET097 they will receive one of four different dose regimens.

Conditions Studied

Type 2 Diabetes Mellitus (T2DM) Obesity in Diabetes

Interventions

  • DRUG Placebo
  • DRUG MET097 Injection

Study Locations (20)

California

  • Research Site US-97202-001012 - Chula Vista
  • Research Site US-97202-001019 - Los Alamitos
  • Research Site US-97202-001021 - Los Angeles
  • Research Site US-97202-001007 - Riverside

Florida

  • Research Site US-97202-001024 - Bradenton
  • Research Site 097202-001001 - Hollywood
  • Research Site 097202-001003 - Tampa

Georgia

  • Research Site 097202-001002 - Decatur
  • Research Site US-97202-001009 - Riverdale
  • Research Site 097202-001005 - Savannah

Illinois

  • Research Site US-97202-001017 - Morton
  • Research Site US-97202-001022 - Naperville

Maryland

  • Research Site US-97202-001015 - Columbia
  • Research Site US-97202-001006 - Gaithersburg

Texas

  • Research Site US-97202-001023 - Plano
  • Research Site US-97202-001013 - Sherman

Kansas

  • Research Site US-97202-001008 - Kansas City

New Jersey

  • Research Site US-97202-001004 - Marlton

Trial Details

FieldValue
Enrollment Target 133 participants
Start Date 2025-03-14
Est. Completion 2026-03
Phase Phase 2

Sponsor

Metsera, a wholly owned subsidiary of Pfizer

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06897202

The ClinicalTrials.gov registry entry for NCT06897202 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 517-participant average among 24 other Type 2 Diabetes Mellitus (T2DM) trials with a reported enrollment target (74% lower). The listed sponsor is Metsera, a wholly owned subsidiary of Pfizer, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Type 2 Diabetes Mellitus (T2DM) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06897202 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT06897202 about?

NCT06897202 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM". This study is designed to test how well once-weekly MET097 (an ultra-long-acting GLP-1 receptor agonist) works to treat adults with obesity or overweight and type 2 diabetes mellitus (T2DM) compared to placebo. MET097 or placebo will be administered to individuals via subcutaneous injection once wee...

What is the current status of trial NCT06897202?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 133 participants. The study started on 2025-03-14. Estimated completion is 2026-03.

What conditions does trial NCT06897202 study?

This clinical trial studies the following conditions: Type 2 Diabetes Mellitus (T2DM), Obesity in Diabetes.

What interventions are being tested in trial NCT06897202?

The interventions under investigation include: Placebo (DRUG), MET097 Injection (DRUG).

Who is sponsoring clinical trial NCT06897202?

This trial is sponsored by Metsera, a wholly owned subsidiary of Pfizer, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06897202 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes Mellitus (T2DM)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 2 Diabetes Mellitus (T2DM)

All registered trials for this condition

Obesity in Diabetes

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.